- Home
- ORI vs IBRX Comparison
ORI vs IBRX Comparison
Compare ORI & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ORI | IBRX |
|---|---|---|
| Founded | 1923 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.8B | 8.2B |
| IPO Year | 1994 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ORI | IBRX |
|---|---|---|
| Price | $38.56 | $8.28 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $43.50 | $14.25 |
| AVG Volume (30 Days) | 1.9M | ★ 13.5M |
| Earning Date | 10-22-2026 | 11-10-2026 |
| Dividend Yield | ★ 9.78% | N/A |
| EPS Growth | 14.81 | ★ 38.71 |
| EPS | ★ 2.63 | N/A |
| Revenue | ★ $9,136,300,000.00 | $113,288,000.00 |
| Revenue This Year | $6.83 | $99.98 |
| Revenue Next Year | $5.72 | $108.29 |
| P/E Ratio | $14.59 | ★ N/A |
| Revenue Growth | 10.99 | ★ 668.31 |
| 52 Week Low | $36.65 | $1.95 |
| 52 Week High | $46.76 | $12.43 |
Technical Indicators
Market Signals| Indicator | ORI | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 47.07 | 43.65 |
| Support Level | $38.38 | $7.71 |
| Resistance Level | $42.88 | $8.51 |
| Average True Range (ATR) | 0.83 | 0.72 |
| MACD | 0.01 | -0.13 |
| Stochastic Oscillator | 37.25 | 17.45 |
Price Performance
Historical ComparisonAbout ORI Old Republic International Corporation
Old Republic International Corp is engaged in the business of insurance underwriting and related services. The company operates in two segments: Specialty Insurance and Title Insurance. The insurance provided by the company includes Automobile Extended Warranty Insurance, Aviation, Commercial Automobile Insurance, Inland Marine, Travel Accident, Workers' Compensation, Financial Indemnity, and others. The company generates the majority of its revenue from Specialty Insurance. The Specialty Insurance provides property and liability insurance principally to commercial clients.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.